Research location
Trier
Germany
Advertisement
Research activity in Trier
GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 128 trials and 132 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Trier
128 linked trials · page 1 of 3A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFNCT07761117 · 2026-08-24 · 1 site observation
RECRUITING
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerNCT07647328 · 2026-06-15 · 1 site observation
RECRUITING
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerNCT07287098 · 2026-05-13 · 1 site observation
RECRUITING
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 DiabetesNCT07112339 · 2025-08-15 · 1 site observation
RECRUITING
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · 2025-08-06 · 1 site observation
RECRUITING
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 2 site observations
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 1 site observation
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation
RECRUITING
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate CancerNCT06517719 · 2024-09-04 · 1 site observation
RECRUITING
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenTNCT06059638 · 2023-12-27 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 · 2022-12-16 · 1 site observation
RECRUITING
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisNCT05344469 · 2022-05-10 · 1 site observation
RECRUITING
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483 · 2021-12-14 · 1 site observation
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation
RECRUITING
Register Schweres Asthma - German Asthma Net e.V.NCT06035289 · 2011-11-01 · 1 site observation
RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's DiseaseNCT07169578 · 2025-09-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Optimizing Clinical Outcomes in Patients Undergoing Mitral Transcatheter Edge-to-edge Repair (M-TEER) for Severe Functional Mitral Regurgitation Towards Improved Guideline-directed Medical TherapyNCT06702527 · 2025-04-01 · 1 site observation
TERMINATED
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)NCT06380738 · 2024-02-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14 · 1 site observation
ACTIVE_NOT_RECRUITING
The RECOVER IV TrialNCT05506449 · 2023-10-28 · 1 site observation
TERMINATED
V-A ECMO AUTO Mode RegistryNCT05759377 · 2023-10-11 · 1 site observation
COMPLETED
A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC PatientsNCT05676203 · 2023-05-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)NCT05296798 · 2022-07-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid ArthritisNCT04871919 · 2021-05-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)NCT04622319 · 2020-12-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT04497597 · 2020-10-16 · 1 site observation
COMPLETED
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)NCT04546009 · 2020-10-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) OutcomesNCT04398654 · 2020-10-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of the MobiusHD® in Patients With Heart FailureNCT04590001 · 2020-10-02 · 1 site observation
UNKNOWN
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney DiseaseNCT04492722 · 2020-10-01 · 1 site observation
TERMINATED
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)NCT04261933 · 2020-02-13 · 1 site observation
COMPLETED
An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid ArthritisNCT04267536 · 2020-02-06 · 1 site observation
COMPLETED
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerNCT04191499 · 2020-01-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)NCT03954132 · 2019-06-07 · 1 site observation
COMPLETED
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerNCT03901339 · 2019-05-08 · 1 site observation
COMPLETED
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)NCT03809988 · 2019-04-05 · 1 site observation
COMPLETED
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR MutationNCT03833154 · 2019-03-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Re-evaluation of Optimal Re-synchronisation Therapy in Patients With Chronic Heart FailureNCT03494933 · 2018-09-01 · 1 site observation
TERMINATED
Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast CancerNCT03503799 · 2018-07-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)NCT03345810 · 2017-12-14 · 1 site observation
COMPLETED
Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)NCT03361865 · 2017-12-04 · 1 site observation
COMPLETED
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line TreatmentNCT06311383 · 2017-10-09 · 1 site observation
COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)NCT03142334 · 2017-06-09 · 1 site observation
COMPLETED
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)NCT03165045 · 2017-05-26 · 1 site observation
COMPLETED
Fear of Activity in Situations (FActS) - Study 2016NCT02898246 · 2016-11-01 · 3 site observations
COMPLETED
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast CancerNCT03096847 · 2016-10-24 · 1 site observation
COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited DiseaseNCT02046733 · 2015-12-18 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.